LONDON, July 3 /PRNewswire/ --     The European electronic lab notebooks (ELN) market is the scene of much
change today as the technology continues to develop rapidly and become more
refined with each passing day. Surpassing the capabilities of traditional
bound laboratory notebooks, ELNs provide a sophisticated communications
platform that enables researchers to share experiment-related information
seamlessly, and even improve or reuse the data. It also satisfies multiple
intellectual property and regulatory requirements, allowing significant
reductions in cycle times in biopharmaceutical R&D.

"Frost & Sullivan expects to see continued and rapid growth from the
specific ELN segment," notes Frost & Sullivan Programme Leader of Drug
Discovery Dr. Amarpreet Dhiman. "One of the key advances in ELN technology
has been the ability to cater to niche end users with specific solutions that
include features such as authentication, sign/witness, audit, notebook record
repository and reporting services with extensive workflow customisation
capabilities."

New analysis from Frost & Sullivan 
(http://www.healthcareandlifesciencesIT.frost.com), European Electronic Lab
Notebooks (ELN) Markets, reveals that these markets earned revenues of 
US$32.3 million in 2006 and estimates this to reach US$143.1 million in 2013.

If you are interested in a virtual brochure, which provides
manufacturers, end users and other industry participants with an overview of
the latest analysis of European Electronic Lab Notebooks (ELN) Markets, then
send an e-mail to Radhika Menon Theodore, Corporate Communications, at
rmtheodore@frost.com with your full name, company name, title, telephone
number, fax number and e-mail address. Upon receipt of the above information,
an overview will be sent to you by e-mail.

Pharmaceuticals and biotechnology companies can now deploy an ELN
platform across their entire R&D processes and gain dramatic improvements in
productivity, collaboration and regulatory compliance. Although ELNs are by
no means the only knowledge system in the drug development and life sciences
chain, they are definitely a key link in the chain that allows end users to
capture and share all the unique and proprietary information they generate.

However, many organisations are concerned about ELN affecting their
processes and ways of working and this has impacted ELN adoption. The extent
of changes that scientists would have to make if they invested in ELNs is
considerable, and could range from training staff and adopting new processes
to upgrading other systems to make them compatible with ELN. This is bound to
lead to some amount of resistance from scientists, particularly since the
traditional paper lab notebook has dominated the scientific environment for
so many years.

"ELNs represent a potential solution for meeting the need of companies to
protect their intellectual property and the needs of end users," says Dr.
Dhiman. "However, before they can be adopted by companies as the principal
method of recording lab data, they must meet the reliability, authenticity
and corroboration criteria established for paper laboratory notebooks."

Security is a particularly important aspect of the ELN database,
especially when entering and updating data in the ELN platform. The challenge
is to maintain an audit trail during such updates and to provide suitable IT
administration features to ensure effective and secure running of the system.

ELNs also need to have a high degree of flexibility that allows
scientists from different disciplines to continue working in ways that best
suit their needs. They need to be sufficiently structured to enable an
ordered and managed approach to record-keeping and must also offer advanced
search capabilities.

"Scientific requirements need to be appropriately articulated so that
ELNs satisfy and accommodate the needs of all labs while simultaneously
working more efficiently and effectively," concludes Dr. Dhiman. "The
European ELN market is expected to continue to grow rapidly over the next
several years as ELNs move into the mainstream and developers continue to
release application-specific solutions as well as develop a host of
interfaces for other add-ons fulfilling end-user demands."

European Electronic Lab Notebooks (ELN) Markets is part of the Healthcare
and Life Sciences IT Growth Partnership Service program, which also includes
research in the following: Virtual Screening Opportunities in Drug Discovery
in Europe, European Bioinformatics Markets, and Data Integration in Life
Science Companies. All research services included in subscriptions provide
detailed market opportunities and industry trends that have been evaluated
following extensive interviews with market participants. Interviews with the
press are available.

Frost & Sullivan, a global growth consulting company, has been partnering
with clients to support the development of innovative strategies for more
than 40 years. The company's industry expertise integrates growth consulting,
growth partnership services, and corporate management training to identify
and develop opportunities. Frost & Sullivan serves an extensive clientele
that includes Global 1000 companies, emerging companies, and the investment
community by providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets, technologies,
econometrics, and demographics. For more information, visit
http://www.frost.com.

Contact:

    Radhika Menon Theodore

    Corporate Communications - Europe
    E: rmtheodore@frost.com

    Melina Trevino

    Corporate Communications - North America
    P: +1-210-247-2440
    F: +1-210-348-1003
    E: melina.trevino@frost.com

    Danielle White

    Corporate Communications - China & Latin America
    P: +1-210-247-2403
    F: +1-210-348-1003
    E: dwhite@frost.com

    Jasminder Kaur

    Corporate Communications - Asia Pacific
    P: +65-6890-0937
    F: +65-6890-0988
    E: jkaur@frost.com

    Shwetha Thomas

    Corporate Communications - South Asia & Middle East
    P: +91-22-4001-3429
    F: +91-22-2832-4713
    E: sthomas@frost.com

    Sharmin Jassal

    Corporate Communications - Australia & New Zealand
    P: +61-2-8247-8900
    F: +61-2-9252-8066
    E: sharmin.jassal@frost.com

    Patrick Cairns

    Corporate Communications - Africa
    P: +27-21-680-3274
    F: +27-21-680-3296
    E: patrick.cairns@frost.com
    http://www.frost.com